Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 151

Results For "EMA"

3514 News Found

Zota Health Care expands Davaindia Network to 1,413 operational stores
News | January 29, 2025

Zota Health Care expands Davaindia Network to 1,413 operational stores

The company remains focused on strengthening its direct retail presence and expanding its reach to more customers across India.


Supriya Lifescience posts Q3 FY25 PAT up at Rs. 46.78 Cr
News | January 28, 2025

Supriya Lifescience posts Q3 FY25 PAT up at Rs. 46.78 Cr

The 33% year-over-year revenue growth and a remarkable 45% surge in gross profit reflect our strong market presence and efficient execution across therapeutic segments


Granules India Q3 FY25 PAT drops 6% to Rs 118 Cr
News | January 27, 2025

Granules India Q3 FY25 PAT drops 6% to Rs 118 Cr

The company said it voluntarily paused production at the Gagillapur plant in September 2024 for risk assessment on account of the USFDA observations


SaponiQx, Probius, and Ginkgo Bioworks to revolutionize vaccine adjuvant development
News | January 27, 2025

SaponiQx, Probius, and Ginkgo Bioworks to revolutionize vaccine adjuvant development

Groundbreaking collaboration harnesses AI-driven insights and advanced manufacturing to create next-generation adjuvants for emerging biological threats


Senores Pharmaceuticals reports revenue of Rs. 288 crore in 9M FY25
News | January 24, 2025

Senores Pharmaceuticals reports revenue of Rs. 288 crore in 9M FY25

PAT after MI is Rs. 41 crore which is 162% increase


Emcure Pharmaceuticals inaugurates R&D centre in Ahmedabad
News | January 24, 2025

Emcure Pharmaceuticals inaugurates R&D centre in Ahmedabad

The Emcure Research Centre (ERC) will drive research across multiple dosage forms, including OSD, injectables, novel drug delivery systems (NDDS), inhalers and topical and transdermal formulations


Syngene reports 18% jump in Q3 FY25 PAT at Rs. 131 Cr
News | January 24, 2025

Syngene reports 18% jump in Q3 FY25 PAT at Rs. 131 Cr

Reported revenue from operations up by 11% to Rs. 944 crores Reported PAT (after exceptional items) up by 18% to Rs. 131 crore


Strides Pharma debuts with ESG rating of 76/100 in the S&P Global’s CSA 2024
Sustainability | January 23, 2025

Strides Pharma debuts with ESG rating of 76/100 in the S&P Global’s CSA 2024

Scored 85/100, 2.3x the industry average in Social and 73/100, 1.8x the industry average in Governance


Dr Reddy’s Labs Q3 FY25 profit up 2% YoY at Rs. 1,413 Cr
News | January 23, 2025

Dr Reddy’s Labs Q3 FY25 profit up 2% YoY at Rs. 1,413 Cr

The revenue from operations in Q3 FY25 is Rs. 8,358.6 crore, up 16% YoY


Budget 2025: Industry expects tax incentives and thrust on affordable healthcare
Policy | January 23, 2025

Budget 2025: Industry expects tax incentives and thrust on affordable healthcare

Expand the scope of the Production-Linked Incentive (PLI) scheme and increase its allocation to cover more pharmaceutical products and raw materials